NIH mobilizes national innovation initiative for COVID-19 diagnostics

Initiative aims to speed delivery of accurate, easy-to-use, scalable tests to all Americans.

Click image to enlarge.NIH

Download(link is external)

The National Institutes of Health today announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic. With a $1.5 billion investment from federal stimulus funding, the newly launched Rapid Acceleration of Diagnostics (RADx) initiative will infuse funding into early innovative technologies to speed development of rapid and widely accessible COVID-19 testing. At the same time, NIH will seek opportunities to move more advanced diagnostic technologies swiftly through the development pipeline toward commercialization and broad availability. NIH will work closely with the U.S. Food and Drug Administration, the Centers for Disease Control and Prevention and the Biomedical Advanced Research and Development Authority (BARDA) to advance these goals.

The stimulus investment supercharges NIH’s strong research efforts already underway focused on prevention and treatment of COVID-19, including the recently announced planned Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership to coordinate the international research response to the pandemic.

“We need all innovators, from the basement to the boardroom, to come together to advance diagnostic technologies, no matter where they are in development,” said NIH Director Francis S. Collins, M.D., Ph.D. “Now is the time for that unmatched American ingenuity to bring the best and most innovative technologies forward to make testing for COVID-19 widely available.”

As part of this initiative, NIH is urging all scientists and inventors with a rapid testing technology to compete in a national COVID-19 testing challenge for a share of up to $500 million over all phases of development. The technologies will be put through a highly competitive, rapid three-phase selection process to identify the best candidates for at-home or point-of-care tests for COVID-19. Finalists will be matched with technical, business and manufacturing experts to increase the odds of success. If certain selected technologies are already relatively far along in development, they can be put on a separate track and be immediately advanced to the appropriate step in the commercialization process. The goal is to make millions of accurate and easy-to-use tests per week available to all Americans by the end of summer 2020, and even more in time for the flu season.

“Americans are innovators and makers,” said Bruce J. Tromberg, Ph.D., director of NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB). “We need American tech experts, innovators and entrepreneurs to step up to one of the toughest challenges we’ve faced as a country, to help get us safely back to public spaces.”

While diagnostic testing has long been a mainstay of public health, newer technologies offer patient- and user-friendly designs, mobile-device integration, reduced cost and increased accessibility both at home and at the point of care. RADx will expand the Point-of-Care Technologies Research Network(link is external) (POCTRN) established several years ago by NIBIB. The network will use a flexible, rapid process to infuse funding and enhance technology designs at key stages of development, with expertise from technology innovators, entrepreneurs and business leaders across the country. POCTRN supports hundreds of investigators from multiple universities and businesses through five technology hubs:

Emory University/Georgia Institute of Technology, Atlanta
Johns Hopkins University, Baltimore
Northwestern University, Evanston, Illinois
University of Massachusetts Medical School, Worcester
Consortia for Improving Medicine with Innovation & Technology (CIMIT) at Harvard Medical School/Massachusetts General Hospital, Boston

Led by the Coordinating Center at CIMIT, the network has assembled expert review boards covering scientific, clinical, regulatory and business domains that will rapidly evaluate technology proposals. In order to roll out new products starting at the end of summer/fall 2020, a rapid, parallel process will allow quick throughput of projects. Projects will be assessed at each milestone and must demonstrate significant progress to receive continued support.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH…Turning Discovery Into Health®